NovoCure (NVCR) Competitors $17.51 +0.62 (+3.67%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$17.66 +0.15 (+0.86%) As of 07/8/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NVCR vs. STVN, GKOS, IRTC, NARI, BLCO, TMDX, SLNO, INSP, NVST, and PRCTShould you be buying NovoCure stock or one of its competitors? The main competitors of NovoCure include Stevanato Group (STVN), Glaukos (GKOS), iRhythm Technologies (IRTC), Inari Medical (NARI), Bausch + Lomb (BLCO), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Inspire Medical Systems (INSP), Envista (NVST), and PROCEPT BioRobotics (PRCT). These companies are all part of the "medical equipment" industry. NovoCure vs. Its Competitors Stevanato Group Glaukos iRhythm Technologies Inari Medical Bausch + Lomb TransMedics Group Soleno Therapeutics Inspire Medical Systems Envista PROCEPT BioRobotics NovoCure (NASDAQ:NVCR) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings. Do insiders & institutionals believe in NVCR or STVN? 84.6% of NovoCure shares are held by institutional investors. 5.5% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is NVCR or STVN more profitable? Stevanato Group has a net margin of 11.14% compared to NovoCure's net margin of -26.41%. Stevanato Group's return on equity of 10.00% beat NovoCure's return on equity.Company Net Margins Return on Equity Return on Assets NovoCure-26.41% -45.46% -13.34% Stevanato Group 11.14%10.00%6.03% Which has better earnings & valuation, NVCR or STVN? Stevanato Group has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovoCure$605.22M3.23-$168.63M-$1.51-11.60Stevanato Group€1.19B6.34€127.45M€0.5149.08 Do analysts prefer NVCR or STVN? NovoCure presently has a consensus target price of $32.43, indicating a potential upside of 85.20%. Given NovoCure's higher probable upside, research analysts clearly believe NovoCure is more favorable than Stevanato Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovoCure 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has more volatility and risk, NVCR or STVN? NovoCure has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Does the media prefer NVCR or STVN? In the previous week, NovoCure had 1 more articles in the media than Stevanato Group. MarketBeat recorded 4 mentions for NovoCure and 3 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 1.30 beat NovoCure's score of 0.48 indicating that Stevanato Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Stevanato Group 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryStevanato Group beats NovoCure on 11 of the 17 factors compared between the two stocks. Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCR vs. The Competition Export to ExcelMetricNovoCureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.88B$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E Ratio-11.6020.8027.0020.10Price / Sales3.23286.98435.75120.29Price / CashN/A41.1936.8257.86Price / Book5.267.487.985.56Net Income-$168.63M-$55.04M$3.16B$248.40M7 Day Performance-2.07%2.44%2.40%4.67%1 Month Performance3.61%1.90%2.19%6.64%1 Year Performance4.16%4.35%33.82%21.31% NovoCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCRNovoCure3.5767 of 5 stars$17.51+3.7%$32.43+85.2%+9.4%$1.88B$605.22M-11.601,488Analyst ForecastSTVNStevanato GroupN/A€24.51-0.5%N/A+35.0%€7.42B€1.19B48.065,521GKOSGlaukos4.556 of 5 stars$103.42+2.0%$134.67+30.2%-16.3%$5.91B$383.48M-43.64780Positive NewsIRTCiRhythm Technologies1.0367 of 5 stars$153.96-0.5%$138.60-10.0%+40.4%$4.92B$618.59M-49.032,000News CoverageNARIInari MedicalN/A$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800BLCOBausch + Lomb3.1036 of 5 stars$13.03+5.1%$15.54+19.3%-8.2%$4.61B$4.79B-12.6513,500Analyst ForecastHigh Trading VolumeTMDXTransMedics Group1.5222 of 5 stars$134.01+1.9%$127.33-5.0%-16.4%$4.53B$441.54M98.54210SLNOSoleno Therapeutics4.7235 of 5 stars$83.78+0.6%$107.10+27.8%+101.0%$4.22BN/A-18.1330INSPInspire Medical Systems4.8272 of 5 stars$129.28-2.4%$211.91+63.9%-1.7%$3.81B$802.80M59.581,246News CoveragePositive NewsNVSTEnvista3.8065 of 5 stars$19.58-0.5%$20.23+3.3%+22.8%$3.32B$2.51B-3.0012,300PRCTPROCEPT BioRobotics2.6605 of 5 stars$57.60+1.2%$90.00+56.3%-9.8%$3.19B$224.50M-33.88430News CoverageAnalyst Forecast Related Companies and Tools Related Companies Stevanato Group Alternatives Glaukos Alternatives iRhythm Technologies Alternatives Inari Medical Alternatives Bausch + Lomb Alternatives TransMedics Group Alternatives Soleno Therapeutics Alternatives Inspire Medical Systems Alternatives Envista Alternatives PROCEPT BioRobotics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVCR) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NovoCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
